funny., I recall the article. What a fiasco. I'm describing something different. IMO, these companies bit off more than they can chew. These companies had cold water thrown over their wet dream of exploiting a market that they assumed would explode in favor of massive uptake. Keep in mind that these companies are not sales organizations, and they no nothing about selling into the CVD space. They're accustomed to following behind BP sales and settling for the abundance left over to justify multiple players. So Generics have a couple of big issues here: They went all in behind Amarin's abysmal sales record. With the intial enthusiasm now behind them, they've joined in and settled into the same sales rut, which we've dreaded since the beginning. Even worse, they're canabalizing not contributing revenue for themselves.
The CEO's must see the writing on the wall. The business case is aweful, and resource allocation is what these executives get paid to distribute for the best return. Like I said, they could get together, and see things the way they are, and make a decision to retract and reenter when the timing makes sense.
ILT
Market Data 
Markets 
AI
